Challenges With a Precision Medicine-Based Approach in Oncology

Holli Dilks, PhD
Published: Monday, Aug 01, 2016


Holli Dilks, PhD, director, Personalized Medicine Operations, Sarah Cannon Research Institute, discusses the challenges associated with having a precision medicine-based approach in the field of oncology.

One of the major challenges oncologists face is tissue availability in the field, Dilks explains. An exciting area of research that is aiming to guide this solution is liquid biopsies. Another obstacle is the ability to conduct a biopsy at the right time; tissue that is relevant to a patient's tumor is important.

Cost is an ongoing factor in precision medicine and the ability to afford such testing and personalized therapies is key, Dilks says. Additionally, resistance mutations that arise from targeted therapies is an issue that needs to be addressed.

Finally, education on the various alternations and how they can impact an individual patient's tumor is necessary, she adds.
 

Holli Dilks, PhD, director, Personalized Medicine Operations, Sarah Cannon Research Institute, discusses the challenges associated with having a precision medicine-based approach in the field of oncology.

One of the major challenges oncologists face is tissue availability in the field, Dilks explains. An exciting area of research that is aiming to guide this solution is liquid biopsies. Another obstacle is the ability to conduct a biopsy at the right time; tissue that is relevant to a patient's tumor is important.

Cost is an ongoing factor in precision medicine and the ability to afford such testing and personalized therapies is key, Dilks says. Additionally, resistance mutations that arise from targeted therapies is an issue that needs to be addressed.

Finally, education on the various alternations and how they can impact an individual patient's tumor is necessary, she adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x